Literature DB >> 2345292

Human T cell lymphotropic virus type I (HTLV-I) among female prostitutes in Kinshasa, Zaire.

S Z Wiktor1, P Piot, J M Mann, N Nzilambi, H Francis, G Vercauteren, W A Blattner, T C Quinn.   

Abstract

Three hundred seventy-seven prostitutes from Kinshasa, Zaire, were enrolled in a study to determine associated risk factors for human immunodeficiency virus type 1 (HIV-1) and human T cell lymphotropic virus type I (HTLV-I) infection. Twelve samples (3.2%) were seropositive for HTLV-I; results for HIV-1 (101 [26.8%]) are reported elsewhere. HTLV-I prevalence increased with age, and seven of the seropositive women originated from the Equateur region, a remote area in northwestern Zaire. The prevalence among women from Equateur (7.2%) was higher than that of women from all other regions (1.8%, P = .02). Presence of HTLV-I antibodies was not associated with frequency or type of sex practice. In a subsequent study, 350 serum samples were obtained from a variety of subjects in the Equateur region in 1986. Nineteen (5.4%) showed antibodies to HTLV-I. These data and a recent report of a cluster of patients with tropical spastic paraparesis from this region suggest that HTLV-I is endemic in the Equateur region of Zaire.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2345292     DOI: 10.1093/infdis/161.6.1073

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

1.  Absence of HTLV-I and HTLV-II infection in prostitutes in the area of Seville, Spain.

Authors:  E J Calderón; E Gómez-Lucia; I Aguado; J A Pineda; M Essex; M Leal
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-09       Impact factor: 3.267

2.  Prevalence of infection by human T-cell leukemia virus types I and II in southern Spain.

Authors:  E J Calderón; C Rey; F J Medrano; J Sánchez-Román; V Soriano; Y Torres; M Ruiz; E Lissen; M Leal
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-08       Impact factor: 3.267

3.  Quantitative assessment of subclinical spasticity in human T-cell lymphotropic virus type I infection.

Authors:  J R Zunt; J O Alarcón; S Montano; W T Longstreth; R Price; K K Holmes
Journal:  Neurology       Date:  1999-07-22       Impact factor: 9.910

Review 4.  Clinical and Public Health Implications of Human T-Lymphotropic Virus Type 1 Infection.

Authors:  Nicolas Legrand; Skye McGregor; Rowena Bull; Sahar Bajis; Braulio Mark Valencia; Amrita Ronnachit; Lloyd Einsiedel; Antoine Gessain; John Kaldor; Marianne Martinello
Journal:  Clin Microbiol Rev       Date:  2022-02-23       Impact factor: 50.129

5.  HIV-1, HIV-2, HTLV-I/II and STD among female prostitutes in Buenos Aires, Argentina.

Authors:  I Zapiola; S Salomone; A Alvarez; M C Scolastico; R A Koessel; J Lemus; C Wainstein; G Muchinik
Journal:  Eur J Epidemiol       Date:  1996-02       Impact factor: 8.082

6.  Low degree of human T-cell leukemia/lymphoma virus type I genetic drift in vivo as a means of monitoring viral transmission and movement of ancient human populations.

Authors:  A Gessain; R C Gallo; G Franchini
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

7.  Post-transplantation HTLV-1 myelopathy in three recipients from a single donor.

Authors:  J J Zarranz Imirizaldu; J C Gomez Esteban; I Rouco Axpe; T Perez Concha; F Velasco Juanes; I Allue Susaeta; J M Corral Carranceja
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-08       Impact factor: 10.154

8.  Epidemiological Aspects and World Distribution of HTLV-1 Infection.

Authors:  Antoine Gessain; Olivier Cassar
Journal:  Front Microbiol       Date:  2012-11-15       Impact factor: 5.640

9.  Human T Lymphotropic Virus Type 1 (HTLV-1): Molecular Biology and Oncogenesis.

Authors:  Priya Kannian; Patrick L Green
Journal:  Viruses       Date:  2010-09-24       Impact factor: 5.818

10.  Population-based Seroprevalence of HTLV-I Infection in Golestan Province, South East of Caspian Sea, Iran.

Authors:  Khodaberdi Kalavi; Abdolvahab Moradi; Alijan Tabarraei
Journal:  Iran J Basic Med Sci       Date:  2013-03       Impact factor: 2.699

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.